Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

Next Previous
Trial Profile

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BBO 10203 (Primary) ; Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Fulvestrant (Primary) ; Oxaliplatin (Primary) ; Ribociclib (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; HER2 negative breast cancer; HER2 positive breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Acronyms BREAKER-101
  • Sponsors BridgeBio Oncology Therapeutics

Most Recent Events

  • 18 Mar 2026 According to a BridgeBio Oncology Therapeutics media release, the data from the trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026.
  • 07 Jan 2026 According to a BridgeBio Oncology Therapeutics media release, the company will host a company webcast on Wednesday, January 7, 2026, at 8:30 am Eastern Time to discuss the data updates from this study.
  • 07 Jan 2026 According to a BridgeBio Oncology Therapeutics media release, the company plans to provide additional data updates, which will include combination data in HER2+ BC, HR+/HER2- PIK3CA mutant BC and KRAS mutant CRC, in 2H 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top